PPIs (Proton Pump Inhibitors)

Heartburn and Indigestion self evaluation tool.


What are PPIs?

PPIs (proton pump inhibitors)Proton pump inhibitors (PPIs) are a commonly prescribed class of medications whose main action is to create a pronounced and long-lasting reduction of stomach acid production. They are used for the treatment of a number of medical conditions, most often for gastro-oesophageal reflux disease (also known as GORD or GERD). They are the most potent inhibitors of acid secretion available today. PPIs produce almost complete reduction of gastric acid secretion and are the drugs of choice for all but mild cases. Patients with severe symptoms often need prolonged treatment, often for years. Many PPIs have been proven to be very safe for short and long term use and have minimal side effects, even in elderly patients.


What are PPIs used for?

Common conditions include:

Virtual Medical Centre Video

Play video on Introduction to Heartburn.Watch a video on Introduction to Heartburn


How do PPIs work?

The stomach produces acid to break down food, so it is easier for our bodies to digest them. In some people, this acid can be harmful to the lining of the stomach and the small bowel. This leads to a breakdown in the lining, causing indigestion, reflux and in some cases ulcers. The acid in the stomach is produced by the hydrogen-potassium-ATPase enzyme system, or the "proton pump". As the name suggests, PPIs stop acid being produced in the stomach by inhibiting the pump's ability to work. This markedly increase the pH of the stomach, and decreases the acidic irritation of the lining of the stomach and small bowel. This in turn provides symptomatic relief and allows the stomach and lower oesophagus to heal.


What are the side effects of PPIs?

PPIs are generally very well tolerated. The incidence of adverse effects is relatively low, affecting 1–3% of individuals. Adverse effects include:

More serious adverse effects, including liver dysfunction and visual disturbances, are infrequent but have been described. An increase in the risk of community-acquired pneumonia has also been noted. Due to the effect on calcium absorption, the risk of bone fractures may be indirectly increased.

Of major interest are the long term effects of PPIs. Long term cellular changes that take place in the stomach may be important in the development of stomach cancers. While the use of PPIs is not currently associated with an increased risk of stomach or colorectal cancer, further studies are required.


What precautions are there for PPIs?

PPIs should be used with care under certain conditions. Tell your doctor if you are:

Before starting PPI treatment, testing should be done to determine that no malignancy is present, as the symptoms of a malignancy may be masked with PPI use, leading to a delay in diagnosis.


Use of PPIs in pregnancy

All of the currently available PPIs are rated as pregnancy category B3, with the exception of rabeprazole (Pariet) which is categorised as B1.

There have been a number of scientific studies investigating the safety of PPIs in pregnancy. These have mostly studied the use of omeprazole (Losec), pantoprazole (Somac) and lansoprazole (Zoton), and have concluded that the use of PPIs in pregnancy is not associated with an increased risk of teratogenesis. However, despite their classification, the use of newer PPIs including rabeprazole (Pariet) and esomeprazole (Nexium) in pregnancy is not recommended due to the lack of scientific data.


What medications do PPIs interact with?

PPIs (proton pump inhibitors)Talk to your doctor before taking any other medicines or herbal remedies with a PPI. The actions of some drugs may be affected by using a PPI.

There are several ways in which a PPI may interact with other drugs, including affecting their absorption or their metabolism.

Drugs for which PPIs affect absorption include:

Drugs for which PPIs affect metabolism include:


PPIs and the elderly

Interactions with other drugs must be considered in elderly patients, as adverse events are more likely to happen with this population. This is for several reasons. Elderly patients tend to be on more medications, and the more medications you are on, the more likely it is that two of them will interact with each other and change the effect.

Another reason is that as most medications are swallowed orally and digestion is started in the stomach, alterations to the environment within the stomach (such as what happens with a PPI) have the potential to change how much of another medication is absorbed. Talk to your GP about all of your medications and the possibility of interactions, as this may change which PPI is used to treat your condition.

The elderly are sometimes more susceptible to the adverse effects of drugs; however, clinical trials suggest that oral pantoprazole is safe and well tolerated in the elderly population for both short-term treatment of GORD and for longer term therapy of other conditions (e.g. ulcers, erosive oesophagitis).


How do you take PPIs?

These medications are available as tablets and capsules. People who have difficulty taking oral medications may use injections. The usual course is four weeks. If there is no improvement after four weeks, you may need to take them for longer, or your doctor may order further tests to determine what else may be helpful. The symptoms you experienced before taking a PPI may come back after you have stopped taking the medication. See your doctor immediately if you vomit blood, notice something that looks like coffee grounds in your vomit, or pass black tarry stools.  

Until recently, these medications were only available though prescription. However, a two week course of Somac Heartburn Relief (pantoprazole) has now been made available through pharmacists.


What are the most common PPIs?

PPIs requiring a prescription from your doctor include:

PPIs available from a pharmacy without a precription include:


More information

Acid reflux and heartburnFor more information on acid reflux and heartburn and related investigations, treatments and supportive care, see Acid Reflux and Heartburn.


Reference

  1. Shi S, Klotz U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64(10): 935-51.
  2. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009; 59(3): 135-53.
  3. Katzung BG. Basic and Clinical Pharmacology (10th edition). USA: McGraw-Hill Companies; 2007.
  4. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on demand' therapy for 6 months. Aliment Pharmacol Ther. 2001; 15(3): 347-54.
  5. Kaspari S, Kupcinskas L, Heinze H, Berghöfer P. Pantoprazole 20mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2005; 17(9): 935-41.
  6. Scholten T, Dekkers CP, Schütze K, Körner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: The ORION trial. Digestion. 2005; 72(2-3): 76-85.
  7. Tsai HH, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: The COMMAND study. Aliment Pharmacol Ther. 2004; 20(6): 657-65.
  8. MIMS Australia [online]. 2007 [cited 11 June 2009]. Available from URL: http://www.mims.com.au
  9. NPS prescribing practice review 34: Proton pump inhibitors in primary care [online]. National Prescribing Service. 2009 [cited 5 July 2009]. Available from URL: http://www.nps.org.au/ health_professionals/ publications/ prescribing_practice_review/ editions/ current/ prescribing_practice_review_34/ proton_pump_inhibitors_in_primary_care   
  10. Nava-Ocampo AA, Velázquez-Armenta EY, Han JY, Koren G. Use of proton pump inhibitors during pregnancy and breastfeeding. Can Fam Physician. 2006; 52: 853-4.
  11. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety. 2006; 29(9): 769-84.
  12. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301(9): 937-44.
  13. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180(7): 713-18.

Drugs used in this treatment:


Article Tools:


E-mail E-mail Bookmark/Add to Favourites Print Print twitter Twitter facebook Facebook

Article Dates:


Created: 25/5/2007 Modified: 17/7/2009 Reviewed: 2/7/2009
Current Sponsors
Proudly brought to you by
Proudly brought to you by
Sponsors Logos
Accreditation and Awards
Accreditations and Awards
Our site has been approved by the HealthInsite Editorial Board to be a HealthInsite information partner site PANDORA is a digital archive dedicated to the preservation of and long term access to Australian online electronic publications of national significance WAITTA Winner 2008 Online secretsFinalist priministeraward
secretsFinalist
Current Sponsors

Virtual Medical Centre

Please be aware that we do not give advice on your individual medical condition,
if you want advice please see your treating physician.

Information on this site must be discussed with your treating doctor.

Virtual Medical Centre © 2002 - 2010 | Privacy Policy Last updated 10 Feb 2010

For Banner Advertising
MediaSmart

Website and videos by
Titan Interactive, Website and Web Design Perth Australia

^ Back to Top